Characterization of amplicons in neuroblastoma: High-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes

Genes Chromosomes and Cancer

Volumn 47, Issue 10, 2008, Pages 819-834

  Fix, Anne ^a   Lucchesi, Carlo ^a   Ribeiro, Agnès ^b   Lequin, Delphine ^a   Pierron, Gaëlle ^b   Schleiermacher, Gudrun ^a,b   Delattre, Olivier ^a,b   Janoueix Lerosey, Isabelle ^a  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPLICON; ARTICLE; CANCER CELL CULTURE; CANCER RECURRENCE; CHROMOSOME; CONTROLLED STUDY; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCATION; GENE MAPPING; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; NEUROBLASTOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

CHILD; CHROMOSOME ABERRATIONS; CHROMOSOME MAPPING; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CHROMOSOMES, HUMAN; DNA, NEOPLASM; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEUROBLASTOMA; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 50249123931     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20583     Document Type: Article

References (45)

1. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc 57:289-300.
2. Brodeur GM. 2003. Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 3:203-216.
3. Carr J, Bown NP, Case MC, Hall AG, Lunec J, Tweddle DA. 2007. High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays. Cancer Genet Cytogenet 172:127-138.
4. Chen QR, Bilke S, Wei JS, Whiteford CC, Cenacchi N, Krasnoselsky AL, Greer BT, Son CG, Westermann F, Berthold F, Schwab M, Catchpoole D, Khan J. 2004. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma. BMC Genomics 5:70.
5. Ciullo M, Debily MA, Rozier L, Autiero M, Billault A, Mayau V, El Marhomy S, Guardiola J, Bernheim A, Coullin P, Piatier-Tonneau D, Debatisse M. 2002. Initiation of the breakage-fusion-bridge mechanism through common fragile site activation in human breast cancer cells: The model of PIP gene duplication from a break at FRA7I. Hum Mol Genet 11:2887-2894.
6. Cohen J. 1960. A coefficient of agreement for nominal scales. Educ Psychol Meas 20:37-46.
7. Corvi R, Amler LC, Savelyeva L, Gehring M, Schwab M. 1994. MYCN is retained in single copy at chromosome 2 band p 23-24 during amplification in human neuroblastoma cells. Proc Natl Acad Sci USA 91:5523-5527.
8. De Preter K, Speleman F, Combaret V, Lunec J, Board J, Pearson A, De Paepe A, Van Roy N, Laureys G, Vandesompele J. 2005. No evidence for correlation of DDX1 gene amplification with improved survival probability in patients with MYCN-amplified neuroblastomas. J Clin Oncol 23:3167-3168.
9. Fix A, Peter M, Pierron G, Aurias A, Delattre O, Janoueix-Lerosey I. 2004. High-resolution mapping of amplicons of the short arm of chromosome 1 in two neuroblastoma tumors by microarray-based comparative genomic hvbridization. Genes Chromosomes Cancer 40:266-270.
10. George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, Fox EA, Meyerson M, Diller L, Fortina P, Look AT, Maris JM. 2007. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS ONE 2:e255.
11. Idbaih A, Marie Y, Pierron G, Brennetot C, Hoang-Xuan K, Kujas M, Mokhtari K, Sanson M, Lejeune J, Aurias A, Delattre O, Delattre JY. 2005. Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 58:483-487.
12. Janoueix-Lerosey I, Novikov E, Monteiro M, Gruel N, Schleiermacher G, Loriod B, Nguyen C, Delattre O. 2004. Gene expression profiling of 1p35-36 genes in neuroblastoma. Oncogene 23:5912-5922.
13. Janoueix-Lerosey I, Hupé P, Maciorowski Z, La Rosa P, Schleiermacher G, Pierron G, Liva S, Barillot E, Delattre O. 2005. Preferential occurrence of chromosome breakpoints within early replicating regions in neuroblastoma. Cell Cycle 4:1842-1846.
14. Jinbo T, Iwamura Y, Kaneko M, Sawaguchi S. 1989. Coamplification of the L-myc and N-myc oncogenes in a neuroblastoma cell line. Jpn J Cancer Res 80:299-301.
15. Kaneko S, Ohira M, Nakamura Y, Isogai E, Nakagawara A, Kaneko M. 2007. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma. J Cancer Res Clin Oncol 133:185-192.
16. La Rosa P, Viara E, Hupe P, Pierron G, Liva S, Neuvial P, Brito I, Lair S, Servant N, Robine N, Manie E, Brennetot C, Janoueix-Lerosey I, Raynal V, Gruel N, Rouveirol C, Stransky N, Stern MH, Delattre O, Aurias A, Radvanyi F, Barillot E. 2006. VAMP: Visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics 22:2066-2073.
17. Lastowska M, Cullinane C, Variend S, Cotterill S, Bown N, O'Neill S, Mazzocco K, Roberts P, Nicholson J, Ellershaw C, Pearson AD, Jackson MS. 2001. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 19:3080-3090.
18. Lastowska M, Viprey V, Santibanez-Koref M, Wappler I, Peters H, Cullinane C, Roberts P, Hall AG, Tweddle DA, Pearson AD, Lewis I, Burchill SA, Jackson MS. 2007. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene 26:7432-7444.
19. Maris JM, Matthay KK. 1999. Molecular biology of neuroblastoma. J Clin Oncol 17:2264-2279.
20. Maris JM, Hogarty MD, Bagatell R, Cohn SL. 2007. Neuroblastoma. Lancet 369:2106-2120.
21. Michels E, Vandesompele J, De Preter K, Hoebeeck J, Vermeulen J, Schramm A, Molenaar JJ, Menten B, Marques B, Stallings RL, Combaret V, Devalek C, De Pacpe A, Versteeg R, Egbert A, Laureys G, Van Roy N, Speleman F. 2007. ArrayCGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer 46:1098-1108.
22. Molenaar JJ, van Sluis P, Boon K, Versteeg R, Caron HN. 2003. Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes Chromosomes Cancer 36:242-249.
23. Mosse YP, Greshock J, Margolin A, Naylor T, Cole K, Khazi D, Hii G, Winter C, Shahzad S, Asziz MU, Biegel JA, Weber BL, Maris JM. 2005. High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes Cancer 43:390-403.
24. Mosse YP, Diskin SJ, Wasserman N, Rinaldi K, Attiyeh EF, Cole K, Jagannathan J, Bhambhani K, Winter C, Maris JM. 2007. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer 46:936-949.
25. Neuvial P, Hupe P, Brito I, Liva S, Manic E, Brennetot C, Radvanyi F, Aurias A, Barillot E. 2006. Spatial normalization of array-CGH data. BMC Bioinformatics 7:264.
26. Nisen PD, Waber PG, Rich MA, Pierce S, Garvin JR, Jr., Gilbert F, Lanzkowsky P. 1988. N-myc oncogene RNA expression in neuroblastoma. J Natl Cancer Inst 80:1633-1637.
27. Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R. 2005. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 167:213-222.
28. Rigaill G, Hupé P, Almeida A, La Rosa P, Meyniel JP, Decraene C, Barillot E. 2008. ITALICS: An algorithm for normalization and DNA copy number calling for Affymetrix SNP arrays. Bioinformatics 24:768-74.
29. Savelyeva L, Schwab M. 2001. Amplification of oncogenes revisited: From expression profiling to clinical application. Cancer Lett 167:115-123.
30. Schleiermacher G, Janoueix-Lerosey I, Combaret V, Derre J, Couturier J, Aurias A, Delattre O. 2003. Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangemenrs of early replicaring chromosome regions in neuroblastoma. Cancer Genet Cytogenet 141:32-42.
31. Schleiermacher G, Raynal V, Janoueix-Lerosey I, Combaret V, Aurias A, Delattre O. 2004. Variety and complexity of chromosome 17 translocations in neuroblastoma. Genes Chromosomes Cancer 39:143-150.
32. Selzer RR, Richmond TA, Pofahl NJ, Green RD, Eis PS, Nair P, Brothman AR, Stallings RL. 2005. Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer 44:305-319.
33. Slave I, Ellenbogen R, Jung WH, Vawter GF, Kretschmar C, Grier H, Korf BR. 1990. myc gene amplification and expression in primary human neuroblastoma. Cancer Res 50:1459-1463.
34. Spieker N, van Sluis P, Beitsma M, Boon K, van Schaik BD, van Kampen AH, Caron H, Versteeg R. 2001. The MEIS1 oncogene is highly expressed in neuroblastoma and amplified in cell line IMR32. Genomics 71:214-221.
35. Spitz R, Oberthuer A, Zapatka M, Brors B, Hero B, Ernestus K, Oestreich J, Fischer M, Simon T, Berthold F. 2006. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer 45:1130-1142.
36. Stallings RL, Nair P, Maris JM, Catchpoole D, McDermott M, O'Meara A, Breatnach F. 2006. High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res 66:3673-3680.
37. Stark GR, Debatisse M, Giulotto E, Wahl GM. 1989. Recent progress in understanding mechanisms of mammalian UNA amplification. Cell 57:901-908.
38. Su WT, Alaminos M, Mora J, Cheung NK, La Quaglia MP, Gerald WL. 2004. Positional gene expression analysis identifies 12q overexpression and amplification in a subset of neuroblastomas. Cancer Genet Cytogenet 154:131-137.
39. Van Roy N, Vandesompele J, Menten B, Nilsson H, De Smet E, Rocchi M, De Paepe A, Pahlman S, Speleman E 2006. Translocation-excision-deletion- amplification mechanism leading to non-syntenic coamplification of MYC and ATBF1. Genes Chromosomes Cancer 45:107-117.
40. Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, Brinkschmidt C, Christiansen H, Combaret V, Lastowska M, Nicholson J, O'Meara A, Plantaz D, Stallings R, Brichard B, Van den Broecke C, De Bie S, De Paepe A, Laureys G, Speleman F. 2005. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 23:2280-2299.
41. Vincent-Salomon A, Gruel N, Lucchesi C, MacGrogan G, Dendale R, Sigal-Zafrani B, Longy M, Raynal V, Pierron G, de Mascarel I, Taris C, Stoppa-Lyonnet D, Pierga JY, Salmon R, Sastre-Garau X, Fourquet A, Delattre O, de Cremoux P, Aurias A. 2007. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 9:R24.
42. Vincent-Salomon A, Lucchesi C, Gruel N, Raynal V, Pierron G, Goudefroye R, Reyal F, Radvanyi F, Salmon R, Thiery J-P, Sastre-Garau X, Sigal-Zafrani B, Fourquet A, Delattre O, Breast Cancer Study Group of the Institut Curie. 2008. Integrated genomics and transcriptomic analyses of ductal carcinoma in situ of the breast. Clin Cancer Res 14:1956-1965.
43. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, Seiser E, Jagannathan J, Shusterman S, Bansal M, Khazi D, Winter C, Okawa E, Grant G, Cnaan A, Zhao H, Cheung NK, Gerald W, London W, Matthay KK, Brodeur GM, Maris JM. 2006. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 66:6050-6062.
44. Weber A, Imisch P, Bergmann E, Christiansen H. 2004. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma. J Clin Oncol 22:2681-2690.
45. Wu Z, Irizarry R, Gentleman R, Martinez-Murillo F, Spencer F. 2004. A model based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 99:909-917.